ESMO Asia Congress 2019

Abstract 140P

Background

Periampullary carcinoma accounts for over 30,000 cancer-related deaths per year in the US. The outcome of the disease differs according to the chosen modality of treatment. This study compared the survival rate between patients undergoing pancreaticoduodenectomy alone versus those receiving neoadjuvant chemotherapy before undergoing the surgery in stage II and III periampullary carcinoma.

Methods

Using the SEER database, we extracted the data of 868 patients with periampullary carcinoma from 2007 to 2011, aged between 40-79 years old. We selected patients with periampullary carcinomas who underwent pancreaticoduodenectomy alone compared to those received neoadjuvant chemotherapy before the surgery.

Results

The highest 5-year survival rate was observed in patients receiving neoadjuvant chemotherapy followed by pancreaticoduodenectomy (20.1%); especially those of stage II (20.1%). However, we found no significant difference in overall survival regarding the patients' gender or race.Table:

140P

Variables	Overall survival	p-value
Therapy Surgery Combined	17.3% 20.1%	0.000**
Stage II III	20.1% 7.9 %	0.000**
Race White Black	19.0% 22.7%	0.732
Sex Male Female	19.3% 19.5%	0.388

Highly significant p-value at ≤ 0.001 Combined: neoadjuvant chemotherapy and surgery.

Conclusions

Patients receiving neoadjuvant chemotherapy before pancreaticoduodenectomy had better 5-year overall survival compared to those undergoing pancreaticoduodenectomy alone; especially stage II.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Mai Abdelkader.

Funding

Has not received any funding.

Disclosure

The author has declared no conflicts of interest.

Resources from the same session

23 Nov 2019